In December, Astra and Daiichi withdrew an application in the EU for the drug to treat a type of lung cancer after feedback from regulatory advisers. Mixed results from a late-stage trial showed ...
Daiichi Sankyo’s board of directors followed the nomination committee’s report in making the appointment. Credit: ArDanMe/Shutterstock. Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed ...
CANTON ‒ Chara Medlock's family last saw her on Dec. 3 when she mentioned plans to go stay with her ex-boyfriend in Massillon, against her mother's advice. Text messages from the 32-year-old ...
Datroway will cost nearly $4,900 per vial, Reuters reported. The treatment will hit U.S. shelves in approximately two weeks, according to Daiichi Sankyo’s announcement of the approval. In a note to ...
DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca. DATROWAY is the ...
(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...
A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...
AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast cancer treatment, a milestone in the companies’ efforts to turn the medicine into a widely used blockbuster. The Food and Drug ...
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. The FDA has greenlighted the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback